Objective: Ephrin A (EphA) receptors are involved in tumorigenesis, metastasis, and angiogenesis, making them attractive candidates for new anti-cancer therapies. Here, we investigated the prognostic value of EphA receptor expression in breast cancer (BC). Methods: We analyzed EphA mRNA levels and survival information through the “Kaplan-Meier plotter” database. In total, we included 3554 breast cancer patients with a median follow-up of 20 years. A 95% confidence interval (CI) and Hazard ratio (HR) were used to assess the overall relative risk of BC outcome. Results: Our results showed that EphA1 (HR = 0.67, 95% CI: 0.6–0.75, p = 6.3 \times 10{}^{-12}), EphA2 (HR = 0.79, 95% CI: 0.7–0.89, p = 5.2 \times 10{}^{-5}), EphA3 (HR = 0.78, 95% CI: 0.69–0.87, p = 1.7 \times 10{}^{-5}), EphA4 (HR = 0.72, 95% CI: 0.61–0.86, p = 3 \times 10{}^{-4}), EphA5 (HR = 0.68, 95% CI: 0.57–0.82, p = 4.3 \times 10{}^{-5}), EphA6 (HR = 0.8, 95% CI: 0.66–0.98, p = 0.027), EphA8 (HR = 0.52, 95% CI: 0.44–0.62, p = 2.6 \times 10{}^{-14}) and EphA10 (HR = 0.58, 95% CI: 0.5–0.68, p = 3.6 \times 10{}^{-11}) were correlated with better relapse-free survival (RFS), while EphA7 (HR = 1.19, 95% CI: 1.02–1.4, p = 0.031) was correlated with a worse RFS in breast cancer patients. Conclusions: Our analyisis demonstrate that profiling EphA receptor mRNA expression in BC patients has prognostic value.